<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04711967</url>
  </required_header>
  <id_info>
    <org_study_id>2020SDUCRCC015</org_study_id>
    <nct_id>NCT04711967</nct_id>
  </id_info>
  <brief_title>Prospective Study of FMT for Acute Intestinal GVHD After Allo-HSCT</brief_title>
  <official_title>Prospective Study of Fecal Microbiota Transplantation for Acute Intestinal GVHD After Allogeneic Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Qilu Hospital of Shandong University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute intestinal GVHD is the main cause of death after allo-HSCT, and FMT is a new treatment&#xD;
      method for this disease. In this prospective study, the investigators will recruit intestinal&#xD;
      GVHD patients to demonstrate the efficacy and safety of FMT.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem&#xD;
      cell transplantation (allo-HSCT), of which intestinal GVHD is a particularly serious one,&#xD;
      which is the main cause of death after allo-HSCT. Recent studies have demonstrated that&#xD;
      intestinal flora imbalance is strongly associated with the risk of infection and mortality in&#xD;
      patients with allo-HSCT. On the basis of this theory, fecal microbiota transplantation (FMT)&#xD;
      may be an effective method for GVHD, that is, fecal suspension from healthy individuals is&#xD;
      inputted into the digestive tract of patients through some methods, so as to restore the&#xD;
      microbial community diversity of patients. In this prospective study, the investigators aimed&#xD;
      to demonstrate the efficacy and safety of this treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in times of stool</measure>
    <time_frame>day 0,day 1, day 2, day 3, day 4, day 5, day 6, day 7, day 14, day 21 and day 28.</time_frame>
    <description>Change in times of stool per day within 28 days after FMT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change in volume of stool</measure>
    <time_frame>day 0,day 1, day 2, day 3, day 4, day 5, day 6, day 7, day 14, day 21 and day 28.</time_frame>
    <description>Change in volume of stool per day within 28 days after FMT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in life quality up to 28 days</measure>
    <time_frame>day 0,day 1, day 2, day 3, day 4, day 5, day 6, day 7, day 14, day 21 and day 28.</time_frame>
    <description>The change quality of patients life within 28 days after FMT is assessed by &quot;EORTC Quality of Life measurement Scale QLQ-C30 (V3.0)&quot; with a score ranged 0~100. And the higher the score, the better the functional status and quality of life</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Acute Graft Versus Host Disease in Intestine</condition>
  <arm_group>
    <arm_group_label>Fecal Microbiota Transplantation group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treat with FMT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treat with traditional medicine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fecal Microbiota Transplantation</intervention_name>
    <description>fecal microbiota transplantation</description>
    <arm_group_label>Fecal Microbiota Transplantation group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>drug</intervention_name>
    <description>drug</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. received allo-HSCT due to a hematopoietic disease&#xD;
&#xD;
          2. corticosteroid resistant/dependent intestinal GVHD&#xD;
&#xD;
          3. ECOG≤2&#xD;
&#xD;
          4. Sign informed Consent&#xD;
&#xD;
          5. No major organ dysfunction&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. uncontrolled or severe infections&#xD;
&#xD;
          2. patients with severe liver and kidney function, cardiopulmonary insufficiency,&#xD;
             epilepsy, and central nervous system disorder&#xD;
&#xD;
          3. high-risk bleeding&#xD;
&#xD;
          4. ANC&lt;0.5×10^9/L or PLT&lt;20x10^9/L&#xD;
&#xD;
          5. hepatitis B, tuberculosis, syphilis, and HIV antibody positive or acute phase of any&#xD;
             infectious disease&#xD;
&#xD;
          6. patients participating in other clinical trials&#xD;
&#xD;
          7. patienta who suffer from mental illness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shuqian Xu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qilu Hospital of Shandong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shuqian Xu</last_name>
    <phone>+86 0531-88382169</phone>
    <email>shuqian.xu@email.sdu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking university people's hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meng p Lv</last_name>
      <phone>13701140918</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shandong university qilu hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shuqian Xu, Ph. D, M. D.</last_name>
      <phone>18560087013</phone>
      <email>shuqian.xu@email.sdu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 30, 2020</study_first_submitted>
  <study_first_submitted_qc>January 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute-graft-versus-host Disease</keyword>
  <keyword>Fecal microbiota transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

